Search Results
Your search for The A matches 34724 pages
Showing 1 - 50ASCO 2026: Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights
The 2026 ASCO Annual Meeting featured numerous high-impact studies in lung cancer. To help readers identify the presentations with the greatest potential to influence clinical practice, The ASCO Post asked lung cancer specialist Apar Kishor Ganti, MD, MS, FASCO, to share his top picks. Dr. Ganti is ...
Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas
Survival and mortality disparities for women with breast cancer are widening between rural and urban areas over time, according to findings from two American Cancer Society studies presented at the 2026 ASCO Quality Care Symposium (Abstracts 208 and 253). The studies found that women from rural...
Amyloidosis: Novel Treatments Could Improve Poor Outcomes
Systemic light chain amyloidosis is a clonal plasma cell disorder that can lead to end-organ dysfunction, with no approved treatment in the relapsed/refractory setting. Given this challenging clinical situation, two studies of novel therapies for this disease reported at the 2026 ASCO Annual...
Chronic Immune-Related Adverse Events Common After Adjuvant Anti–PD-1 Therapy for Melanoma
Nearly half of patients with resected high-risk melanoma treated with adjuvant anti–PD-1 therapy developed chronic immune-related adverse events, and more than one-third still had ongoing toxicity after a median follow-up of more than 5 years. Roma A. Kankaria, MD, and colleagues reported the...
ASCO and WHO Formalize Partnership
Cancer is one of the leading causes of morbidity and mortality worldwide, affecting 92% of families around the world, according to the latest estimates from the World Health Organization (WHO) Global status report on cancer 2026. The highest health, social, and economic burdens occur in low- and...
Study Supports Universal Germline Genetic Testing Regardless of Age at Cancer Diagnosis
Universal germline genetic testing after an individual receives a cancer diagnosis may help to uncover hereditary cancer risks in the patient's family, according to findings published in Cancer Discovery. In a study of a pan–solid tumor cohort, researchers found enriched germline pathogenic...
FDA Approves Expanded Indication for Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBC
On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved the IL-15 receptor agonist nogapendekin alfa inbakicept-pmln (Anktiva) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adults with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC). This...
Facilitated Cascade Genetic Testing Improves Uptake Among Relatives of BRCA1/2 Variant Carriers
According to findings from a randomized controlled trial reported by Wilke et al in the Journal of Clinical Oncology, a clinician-facilitated approach to cascade genetic testing significantly increased genetic testing uptake among first-degree relatives of individuals with BRCA1 or BRCA2 pathogenic ...
Sitagliptin Added to Standard Prophylaxis Reduces Risk of Acute GVHD Following Alternative Donor Transplantation
Adding the selective, oral dipeptidyl peptidase-4 inhibitor, sitagliptin, to antithymocyte globulin–based prophylaxis significantly reduced the incidence of grade 2 to 4 acute graft-vs-host disease (GVHD) among patients undergoing alternative donor hematopoietic stem-cell transplantation, according ...
Automated vs Handheld Ultrasound for Breast Cancer Screening
A new study by Rauscher et al in the Journal of the American College of Radiology has found that automated breast ultrasound (ABUS) and handheld ultrasound (HHUS) had similar cancer detection rates in women with dense breasts, whereas ABUS had a lower false-positive rate. These data demonstrate...
ASCO Remembers Dr. Rachna T. Shroff, Expert in Gastrointestinal Cancers and Dedicated ASCO Volunteer
ASCO joins the oncology community in mourning the death of Rachna T. Shroff, MD, MS, FASCO, a renowned expert specializing in gastrointestinal (GI) cancers and a dedicated ASCO volunteer. Dr. Shroff passed away following a battle with an aggressive cancer. After completing her training, Dr....
Implementing Massage and Acupuncture to Achieve Better Pain Management in Oncology Care: An Overview of the IMAGINE Project
Pain is an incredibly challenging symptom that affects over 40% of patients with cancer in active treatment1 and up to two in three patients with advanced cancer.2 Analgesic pain medications including opioids have been the predominant pain management strategy; however, their use is limited by...
Anitocabtagene Autoleucel Shows High Response Rate in Heavily Pretreated Relapsed/Refractory Multiple Myeloma
Anitocabtagene autoleucel (anito-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, produced responses in all treated patients in a phase I study of heavily pretreated relapsed or refractory multiple myeloma, with 79% achieving a...
Remote Exercise Program Reduces Cancer-Related Fatigue, Improves Quality of Life for Patients Undergoing Immunotherapy
A supervised remote exercise program improved the quality of life of patients with cancer undergoing immunotherapy, primarily by reducing cancer fatigue, according to findings from a secondary analysis of a phase II trial that will be presented at the 2026 ASCO Quality Care Symposium (Abstract...
Financial Navigation Support May Help Reduce Financial Toxicity for Some People With Advanced Cancer
Results from the randomized nationwide CREDIT trial showed that a financial navigation support program does not broadly reduce financial hardship for people being treated for advanced cancer. However, it can help a subgroup of people: those with existing financial and social resources that make...
The Wistar Institute Names New President and Chief Executive Officer
The Wistar Institute’s Board of Trustees has appointed Ronny Drapkin, MD, PhD, a physician-scientist and ovarian cancer researcher at the University of Pennsylvania Perelman School of Medicine, to be the Institute’s next President and Chief Executive Officer, effective November 30, 2026. Dr....
Early Research Links Abdominal Obesity to Increased Lung Cancer Risk
Findings from a recent study published in the Journal of Thoracic Oncology challenge the idea that an obesity paradox contributes to reduced lung cancer risk—instead, the data suggested that obesity may be associated with enhanced lung carcinogenesis. “Overall, our data clearly associate central ...
HER2-Negative Advanced Gastric Cancers: First-Line Retlirafusp Alfa Combination Demonstrates Survival Benefit
The addition of retlirafusp alfa to capecitabine and oxaliplatin (CAPOX) significantly prolonged overall survival compared with chemotherapy alone as first-line treatment for patients with unresectable, locally advanced or metastatic, HER2-negative gastric or gastroesophageal junction...
Study Identifies Insurance and Cost Barriers to Oral Therapies for Blood Cancers
A nationwide study of patients with blood cancers found that most prescriptions for specialty oral anticancer medications were initially rejected by insurers, and many patients did not fill their prescriptions even after receiving approval. The findings, reported by Doshi et al in the Journal of...
FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer
On October 8, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients aged 2 years and older with stage III mismatch repair–deficient (dMMR) colon cancer. The FDA...
Robotic Esophagectomy Improves Lymph Node Yield in Esophageal Cancer
According to results from the phase III ROBOT-2 trial published in JAMA Surgery, robot-assisted minimally invasive esophagectomy provided a more radical lymphadenectomy than conventional minimally invasive esophagectomy in patients with esophageal or esophagogastric junction adenocarcinoma. Berlth...
Starting Surveillance Colonoscopy After High-Risk Adenoma Removal: When Is the Right Time?
Surveillance colonoscopy at 5 years after removal of high-risk adenomas was noninferior to surveillance at 3 years in terms of colorectal cancer incidence during the first 5 years after adenoma removal, according to an interim analysis of the randomized EPoS II trial reported by Jover et al in The...
ACS Report Highlights Cancer Burden and Screening Disparities in U.S. Hispanic Population
The cancer distribution in the Hispanic population is distinct from the general population in the United States, according to a statistics report from the American Cancer Society (ACS) published in CA: A Cancer Journal for Clinicians. The report indicated fewer lung and urinary bladder cancers,...
Study Supports Sentinel Lymph Node Biopsy After Chemotherapy in Locally Advanced Breast Cancer
A prospective study found that sentinel lymph node biopsy may be an accurate method of axillary staging in selected patients with locally advanced breast cancer who achieve a clinical nodal response to neoadjuvant chemotherapy—potentially allowing some patients to avoid axillary lymph node...
Charles M. Perou, PhD, Honored With 2026 William L. McGuire Memorial Lecture Award
Charles M. Perou, PhD, will receive the William L. McGuire Memorial Lecture Award during the San Antonio Breast Cancer Symposium 2026 (SABCS), to be held December 8 to 11 at the Henry B. González Convention Center in San Antonio, Texas. He will present his award lecture, titled “Quantitative...
HER2-Positive Breast Cancer: FDA Approves Triplet for Maintenance Therapy
On October 7, the U.S. Food and Drug Administration (FDA) approved tucatinib (Tukysa), a HER2-targeted tyrosine kinase inhibitor, in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast...
GLP-1 Receptor Agonist Use Linked to Lower Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease
Use of GLP-1 receptor agonist was significantly associated with a lower 5-year incidence of colorectal cancer among patients with inflammatory bowel disease (IBD), including those with concomitant type 2 diabetes, according to findings presented at the 2026 ASCO Breakthrough Meeting in Singapore.1...
Pediatric Bone Sarcoma Gets First NCCN Guidelines
The National Comprehensive Cancer Network (NCCN) has released its first-ever NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for pediatric bone sarcomas. These new guidelines offer a comprehensive set of treatment recommendations for a challenging pediatric cancer, and offer...
2026 Albany Prize Awardees Announced
Tony Hunter, PhD, and Dennis J. Slamon, MD, PhD, have been awarded the 2026 Albany Medical Center Prize in Medicine and Biomedical Research. The two distinguished recipients are being recognized for their breakthrough discoveries that have revolutionized our understanding of the molecular...
Residual Ovarian Cancer Risk in BRCA Carriers May Inform Timing of Preventive Surgery
Among older BRCA carriers who remain in good health, the residual risk of ovarian cancer may be high enough to support consideration of preventive surgery, according to findings from a prospective cohort study reported in JAMA Surgery. Giannakeas et al also found that BRCA1 carriers who defer...
Replacing Intensive Chemotherapy With Blinatumomab Improves Outcomes in High-Risk Pediatric Acute Lymphoblastic Leukemia
Replacing two cycles of intensive chemotherapy with blinatumomab significantly improved event-free survival in children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL), while also reducing several serious treatment-related toxicities. Schrappe et al reported results from...
The Molecular Watchman: Why Measurable Residual Disease Testing Is Redefining Treatment and Surveillance in Colorectal and Bladder Cancers
Implementing a personalized medicine approach in oncology increasingly includes the use of measurable residual disease (MRD) testing to detect molecular evidence of cancer that remains after treatment, enabling more precise risk stratification, earlier intervention, and more informed treatment...
Pediatric and Adolescent Colorectal Carcinoma: A Retrospective Analysis
Rates of advanced-stage colorectal cancer are climbing in young patients, marking a need for increased vigilance, according to data presented during the American Academy of Pediatrics 2026 National Conference & Exhibition (Abstract 02-204). Investigators retrospectively examined the medical...
Tile-Based Radiation Outperforms Postoperative Stereotactic Radiation Therapy in Resected Brain Metastases
According to findings from a phase III trial reported by Weinberg et al in the Journal of Clinical Oncology, intraoperative tile-based radiation therapy with cesium-131 significantly improved surgical bed control compared with postoperative stereotactic radiation therapy in patients undergoing...
AI-Extracted Chart Data for Expanding Surgical Oncology Learnings
Large language models (LLMs) are capable of extracting structured data directly from electronic medical records, expanding data sets available for research, training, and developing artificial intelligence (AI) models. In a session on operating rooms of the future at Cleveland Clinic’s A.I. Summit...
Wildfire-Related Fine Particulate Matter Linked to Higher Mortality in Older Patients With Lung Cancer
Long-term exposure to fine particulate matter from wildfire smoke was associated with a higher risk of death among older patients with lung cancer, and wildfire-related particulate matter appeared more harmful than nonwildfire air pollution at the same exposure level. Zhang et al reported the...
Global Gaps in Cancer-Control Expenditure Data Identified
There is a large global gap in expenditure data on cancer control, and available data suggest generally low and unequal expenditure across countries and territories, according to a cross-sectional analysis published by Figi et al in The Lancet �Oncology. “The paucity of publicly available...
Verifying the Seen and Unseen by AI in Cancer Imaging
Artificial intelligence (AI) can be used in medical imaging and diagnostics to enhance physician capabilities, but also to identify features that humans are not able to see. In research settings, AI has already demonstrated that ability to identify biomarkers from routine medical images and guide...
Alberto A. Chiappori, MD, on Relapsed or Refractory SCLC: Phase I Study of Novel CAR T-Cell Therapy
Alberto A. Chiappori, MD, of Moffitt Cancer Center, discusses findings from a phase I trial looking at the safety and efficacy of LB2102, an autologous CAR-T cell therapy targeting DLL3 and armored with a dominant-negative TGF-beta receptor, in pretreated patients with small cell lung cancer (SCLC) ...
Autonomous AI Triaged Urgent Suspected Skin Cancer Referrals in Real-World Implementation Study
Autonomous artificial intelligence (AI) as a medical device could be used to address rising dermatology service needs, freeing up clinical capacity to provide about 8,500 more dermatology appointments within 16 months, according to findings from a real-world U.K. study presented at the European...
Giannis S. Mountzios, MD, on Metastatic PD-L1–High NSCLC: Sacituzumab Govitecan/Pembrolizumab
Giannis S. Mountzios, MD, of Henry Dunant Hospital Center, reviews primary results from the phase III EVOKE-03/KEYNOTE D46 trial, which evaluated first-line sacituzumab govitecan in combination with pembrolizumab in patients with metastatic non–small cell lung cancer (NSCLC) and a PD-L1 tumor...
ER-Positive, HER2-Negative Advanced Breast Cancer: Giredestrant Plus Everolimus
Patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer experienced significantly improved progression-free survival when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD),...
FDA Approves First-Line Pirtobrutinib for CLL/SLL
On October 2, the U.S. Food and Drug Administration (FDA) approved pirtobrutinib (Jaypirca) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion. Efficacy and Safety Efficacy was evaluated in the randomized,...
Lung Cancer: AI Model May Predict Pneumonitis Risk From Immunotherapy
A deep learning foundation model was able to predict pneumonitis risk from immune checkpoint inhibition therapy in patients with non–small cell lung cancer (NSCLC) based on baseline computed tomography (CT) scans, according to findings published in the Journal for ImmunoTherapy of Cancer....
Pembrolizumab/Olaparib Strategy in BRCA-Nonmutated Advanced Ovarian Cancer
A pembrolizumab/olaparib strategy significantly improved progression-free survival in patients with newly diagnosed BRCA-nonmutated advanced epithelial ovarian cancer, although overall survival was not improved. Ignace Vergote, MD, PhD, and colleagues reported results from the phase III...
Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality
Cancer death rates fell for both men and women from 2019 to 2023, continuing a downward trend that has lasted more than 20 years, according to the 2026 Annual Report to the Nation on the Status of Cancer, published by Henley et al in the journal Cancer. The continued decline in cancer deaths is...
Are Narrower Negative Margins Linked to Higher Risk of DCIS Recurrence?
Among patients with ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery, negative surgical margins narrower than 2 mm were not associated with a significantly higher risk of ipsilateral recurrence compared with margins of at least 2 mm—except among patients younger than age...
IARC Panel Provides International Determination on Lung Cancer Screening's Benefits and Harms
The International Agency for Research on Cancer (IARC) has published a comprehensive international evaluation on lung cancer screening in The New England Journal of Medicine. Screening has emerged as a complementary approach to tobacco control and other methods for preventing lung cancer to reduce...
Can Long Distance Running Be a Risk Factor for Early-Onset Colorectal Cancer?
Colorectal cancer, once thought of as mainly a disease of the aging, is rising in younger adults by nearly 3% per year and is now a leading cause of cancer-related death among individuals under the age of 50.1 According to the American Cancer Society, in 2026, nearly 159,000 individuals will be...
FDA Launches Effort to Expand Scientific Expertise, Consumer Voice to Advisory Committees
The U.S. Food and Drug Administration (FDA) recently announced a broad, nationwide recruitment effort to expand the range of qualified voices and perspectives on its advisory committees. The FDA is publishing two Federal Register notices: one seeking qualified scientific, technical, and...
